2021 Nov: The first clinical trial of South Korea’s homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals, has recently gotten under way.
Institut Sains dan Teknologi Termaju Korea (KAIST) mengumumkan pada hari Rabu bahawa percubaan klinikal Fasa 1b terapi sel CAR-Tnya sedang dijalankan di Pusat Perubatan Samsung di Seoul. Percubaan sedang dijalankan dengan 10 pesakit Korea yang telah kambuh dan limfoma sel B besar meresap refraktori. Hak pemasaran untuk saluran paip telah dipindahkan dari universiti kepada syarikat Curocell, yang diasaskan bersama oleh Profesor Kim Chan-hyuk. Curocell bertanggungjawab ke atas program pembangunan klinikal revolusioner imunoterapi.
In addition, a Phase 2 percubaan klinikal involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for reseptor antigen chimeric T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Anda mungkin suka membaca: Terapi T-Cell CAR di Korea
Penemuan kajian itu dibentangkan dalam artikel yang diterbitkan dalam talian dalam Terapi Molekul edisi Oktober.
